ASCLETIS-B (01672) Rises Over 4% Again as ASC36 and ASC35 Combo Advances to Clinical Development

Stock News

昨天

ASCLETIS-B (01672) surged over 4% again, trading at HK$11.68 by the latest update, up 3.55%, with a turnover of HK$8.54 million. The company announced that its monthly next-generation amylin receptor agonist ASC36 and monthly next-generation GLP-1R/GIPR dual-target agonist ASC35 combination therapy has entered the clinical development stage. ASCLETIS-B expects to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) in Q2 2026 for the ASC36 and ASC35 combo in obesity treatment.

"Based on these encouraging preclinical data, we believe the ASC36 and ASC35 combination has the potential to achieve more significant weight loss than monotherapy in obese patients," said Dr. Jinzi Wu, Founder, Chairman, and CEO of ASCLETIS-B. "Our growing pipeline demonstrates our platform's capability in designing, optimizing, and developing ultra-long-acting once-monthly subcutaneous peptide therapies."

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1190620025"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1190620025\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1190620025?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-13 10:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1190620025","market":"fut","top_or_hot":-1,"title":"ASCLETIS-B (01672) Rises Over 4% Again as ASC36 and ASC35 Combo Advances to Clinical Development","media":"Stock News","content":"<p>ASCLETIS-B (01672) surged over 4% again, trading at HK$11.68 by the latest update, up 3.55%, with a turnover of HK$8.54 million. The company announced that its monthly next-generation amylin receptor agonist ASC36 and monthly next-generation GLP-1R/GIPR dual-target agonist ASC35 combination therapy has entered the clinical development stage. ASCLETIS-B expects to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) in Q2 2026 for the ASC36 and ASC35 combo in obesity treatment.</p>\n<p>\"Based on these encouraging preclinical data, we believe the ASC36 and ASC35 combination has the potential to achieve more significant weight loss than monotherapy in obese patients,\" said Dr. Jinzi Wu, Founder, Chairman, and CEO of ASCLETIS-B. \"Our growing pipeline demonstrates our platform's capability in designing, optimizing, and developing ultra-long-acting once-monthly subcutaneous peptide therapies.\"</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ASCLETIS-B (01672) Rises Over 4% Again as ASC36 and ASC35 Combo Advances to Clinical Development</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nASCLETIS-B (01672) Rises Over 4% Again as ASC36 and ASC35 Combo Advances to Clinical Development\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-13 10:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>ASCLETIS-B (01672) surged over 4% again, trading at HK$11.68 by the latest update, up 3.55%, with a turnover of HK$8.54 million. The company announced that its monthly next-generation amylin receptor agonist ASC36 and monthly next-generation GLP-1R/GIPR dual-target agonist ASC35 combination therapy has entered the clinical development stage. ASCLETIS-B expects to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) in Q2 2026 for the ASC36 and ASC35 combo in obesity treatment.</p>\n<p>\"Based on these encouraging preclinical data, we believe the ASC36 and ASC35 combination has the potential to achieve more significant weight loss than monotherapy in obese patients,\" said Dr. Jinzi Wu, Founder, Chairman, and CEO of ASCLETIS-B. \"Our growing pipeline demonstrates our platform's capability in designing, optimizing, and developing ultra-long-acting once-monthly subcutaneous peptide therapies.\"</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1515","symbol_name":"抗疫概念","start_time":0,"source_url":"","article_id":"1190620025","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1190620025","pubTimestamp":1763001025,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"ASCLETIS-B (01672) surged over 4% again, trading at HK$11.68 by the latest update, up 3.55%, with a turnover of HK$8.54 million. The company announced that its monthly next-generation amylin receptor...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1515":"抗疫概念","BK1191":"制药","BK1161":"生物科技","BK1574":"生物医药B类股","01477":"欧康维视生物-B","01672":"歌礼制药-B"},"translate_title":"ASC36和ASC35组合进入临床开发，歌礼-B(01672)再次涨超4%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01477":1,"01672":1},"content_text":"ASCLETIS-B (01672) surged over 4% again, trading at HK$11.68 by the latest update, up 3.55%, with a turnover of HK$8.54 million. The company announced that its monthly next-generation amylin receptor agonist ASC36 and monthly next-generation GLP-1R/GIPR dual-target agonist ASC35 combination therapy has entered the clinical development stage. ASCLETIS-B expects to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) in Q2 2026 for the ASC36 and ASC35 combo in obesity treatment.\n\"Based on these encouraging preclinical data, we believe the ASC36 and ASC35 combination has the potential to achieve more significant weight loss than monotherapy in obese patients,\" said Dr. Jinzi Wu, Founder, Chairman, and CEO of ASCLETIS-B. \"Our growing pipeline demonstrates our platform's capability in designing, optimizing, and developing ultra-long-acting once-monthly subcutaneous peptide therapies.\"","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}